FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus

Keyur Patel, Mireen Friedrich-Rust, Yoav Lurie, Mircea Grigorescu, Carol Stanciu, Chuan Mo Lee, Eugene R. Schiff, Dieter Häussinger, Michael P. Manns, Guido Gerken, Isabelle Colle, Michael Torbenson, Erik Pulkstenis, G. Mani Subramanian, John G. McHutchison, Stefan Zeuzem

Research output: Contribution to journalArticle

Abstract

AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan® transient elastography (TE) was performed during treatment in a patient subset. RESULTS: Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71% (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P <0.001). Combined FS/TE had 97% accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P <0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. CONCLUSION: FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.

Original languageEnglish (US)
Pages (from-to)4581-4589
Number of pages9
JournalWorld Journal of Gastroenterology
Volume17
Issue number41
DOIs
StatePublished - Nov 7 2011

Fingerprint

Elasticity Imaging Techniques
Chronic Hepatitis C
Hepacivirus
Therapeutics
Genotype
Biopsy
Interferons
Sensitivity and Specificity

Keywords

  • Albinterferon alfa-2b
  • FibroScan
  • FibroSURE
  • Hepatitis C virus
  • Interferon
  • Sustained virological response
  • Transient elastography

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Patel, K., Friedrich-Rust, M., Lurie, Y., Grigorescu, M., Stanciu, C., Lee, C. M., ... Zeuzem, S. (2011). FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus. World Journal of Gastroenterology, 17(41), 4581-4589. https://doi.org/10.3748/wjg.v17.i41.4581

FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus. / Patel, Keyur; Friedrich-Rust, Mireen; Lurie, Yoav; Grigorescu, Mircea; Stanciu, Carol; Lee, Chuan Mo; Schiff, Eugene R.; Häussinger, Dieter; Manns, Michael P.; Gerken, Guido; Colle, Isabelle; Torbenson, Michael; Pulkstenis, Erik; Mani Subramanian, G.; McHutchison, John G.; Zeuzem, Stefan.

In: World Journal of Gastroenterology, Vol. 17, No. 41, 07.11.2011, p. 4581-4589.

Research output: Contribution to journalArticle

Patel, K, Friedrich-Rust, M, Lurie, Y, Grigorescu, M, Stanciu, C, Lee, CM, Schiff, ER, Häussinger, D, Manns, MP, Gerken, G, Colle, I, Torbenson, M, Pulkstenis, E, Mani Subramanian, G, McHutchison, JG & Zeuzem, S 2011, 'FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus', World Journal of Gastroenterology, vol. 17, no. 41, pp. 4581-4589. https://doi.org/10.3748/wjg.v17.i41.4581
Patel, Keyur ; Friedrich-Rust, Mireen ; Lurie, Yoav ; Grigorescu, Mircea ; Stanciu, Carol ; Lee, Chuan Mo ; Schiff, Eugene R. ; Häussinger, Dieter ; Manns, Michael P. ; Gerken, Guido ; Colle, Isabelle ; Torbenson, Michael ; Pulkstenis, Erik ; Mani Subramanian, G. ; McHutchison, John G. ; Zeuzem, Stefan. / FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus. In: World Journal of Gastroenterology. 2011 ; Vol. 17, No. 41. pp. 4581-4589.
@article{5e51caf7819a4f03afc76b5ae80f4475,
title = "FibroSURE™ and FibroScan{\circledR} in relation to treatment response in chronic hepatitis C virus",
abstract = "AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan{\circledR} transient elastography (TE) was performed during treatment in a patient subset. RESULTS: Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71{\%} (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P <0.001). Combined FS/TE had 97{\%} accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P <0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. CONCLUSION: FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.",
keywords = "Albinterferon alfa-2b, FibroScan, FibroSURE, Hepatitis C virus, Interferon, Sustained virological response, Transient elastography",
author = "Keyur Patel and Mireen Friedrich-Rust and Yoav Lurie and Mircea Grigorescu and Carol Stanciu and Lee, {Chuan Mo} and Schiff, {Eugene R.} and Dieter H{\"a}ussinger and Manns, {Michael P.} and Guido Gerken and Isabelle Colle and Michael Torbenson and Erik Pulkstenis and {Mani Subramanian}, G. and McHutchison, {John G.} and Stefan Zeuzem",
year = "2011",
month = "11",
day = "7",
doi = "10.3748/wjg.v17.i41.4581",
language = "English (US)",
volume = "17",
pages = "4581--4589",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "41",

}

TY - JOUR

T1 - FibroSURE™ and FibroScan® in relation to treatment response in chronic hepatitis C virus

AU - Patel, Keyur

AU - Friedrich-Rust, Mireen

AU - Lurie, Yoav

AU - Grigorescu, Mircea

AU - Stanciu, Carol

AU - Lee, Chuan Mo

AU - Schiff, Eugene R.

AU - Häussinger, Dieter

AU - Manns, Michael P.

AU - Gerken, Guido

AU - Colle, Isabelle

AU - Torbenson, Michael

AU - Pulkstenis, Erik

AU - Mani Subramanian, G.

AU - McHutchison, John G.

AU - Zeuzem, Stefan

PY - 2011/11/7

Y1 - 2011/11/7

N2 - AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan® transient elastography (TE) was performed during treatment in a patient subset. RESULTS: Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71% (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P <0.001). Combined FS/TE had 97% accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P <0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. CONCLUSION: FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.

AB - AIM: To compare histological endpoint assessment using noninvasive alternatives to biopsy during treatment in a chronic hepatitis C virus (HCV) cohort. METHODS: Patients with chronic HCV were randomized to receive interferon-based therapy for 24 (genotypes 2/3) or 48 (genotype 1) wk. FibroSURE™ (FS) was assessed at baseline and at week-12 post-treatment follow-up. Baseline biopsy for METAVIR was assessed by a single pathologist. FibroScan® transient elastography (TE) was performed during treatment in a patient subset. RESULTS: Two thousand and sixty patients (n = 253 in Asia) were classified as METAVIR F0-1 (n = 1682) or F2-4 (n = 378). For F2-4, FS (n = 2055) had sensitivity and specificity of 0.87 and 0.61, respectively, with area under the receiver-operating curve of 0.82; corresponding values for TE (n = 214) and combined FS/TE (n = 209) were 0.77, 0.88 and 0.88, and 0.93, 0.68 and 0.88. Overall FS/TE agreement for F2-4 was 71% (κ = 0.41) and higher in Asians vs non-Asians (κ = 0.86 vs 0.35; P <0.001). Combined FS/TE had 97% accuracy in Asians (n = 33). Baseline FS (0.38 vs 0.51, P <0.001) and TE (8.0 kPa vs 11.9 kPa, P = 0.006) scores were lower in patients with sustained virological response than in nonresponders, and were maintained through follow-up. CONCLUSION: FS and TE may reliably differentiate mild from moderate-advanced disease, with a potential for high diagnostic accuracy in Asians with chronic HCV.

KW - Albinterferon alfa-2b

KW - FibroScan

KW - FibroSURE

KW - Hepatitis C virus

KW - Interferon

KW - Sustained virological response

KW - Transient elastography

UR - http://www.scopus.com/inward/record.url?scp=82155187178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82155187178&partnerID=8YFLogxK

U2 - 10.3748/wjg.v17.i41.4581

DO - 10.3748/wjg.v17.i41.4581

M3 - Article

VL - 17

SP - 4581

EP - 4589

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 41

ER -